Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

24.05B

Market cap24.05B

Price-Earnings ratio

65.37

Price-Earnings ratio65.37

Dividend yield

—

Dividend yield—

Average volume

2.13M

Average volume2.13M

High today

$123.96

High today$123.96

Low today

$117.88

Low today$117.88

Open price

$123.96

Open price$123.96

Volume

1.60M

Volume1.60M

52 Week high

$132.60

52 Week high$132.60

52 Week low

$89.25

52 Week low$89.25

Stock Snapshot

With a market cap of 24.05B, Incyte(INCY) trades at $118.01. The stock has a price-to-earnings ratio of 65.37.

During the trading session on 2026-11-05, Incyte(INCY) shares reached a daily high of $123.96 and a low of $117.88. At a current price of $118.01, the stock is +0.1% higher than the low and still -4.8% under the high.

Trading activity shows a volume of 1.6M, compared to an average daily volume of 2.13M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $132.60 and a low of $89.25.

INCY News

Benzinga 13h

$1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today - Benzinga

...

Simply Wall St 16h

Is Incyte Undervalued On Trial Progress And Raised Sales Guidance?

Incyte (INCY) has just put its oncology pipeline and financial guidance in the spotlight, with fresh trial data on KRAS G12D and MSS colorectal cancer therapies...

TipRanks 3d

Incyte Earnings Call Highlights Growth and Pipeline Expansion

Incyte ((INCY)) has held its Q3 earnings call. Read on for the main highlights of the call. Incyte’s earnings call struck a strongly positive tone, supported b...

Analyst ratings

48%

of 31 ratings

Buy

45.2%

Hold

48.4%

Sell

6.5%

More INCY News

Simply Wall St 4d

Did Earnings Beat Just Shift Incyte's Investment Narrative?

Incyte reported Q3 2026 revenue of US$1,557.2m and a quarterly net loss of US$784.8m, while still raising full year 2026 sales guidance to a range of US$5,210m...

Simply Wall St 6d

Incyte Starts Phase 1 Colorectal Cancer Combination Trial

Adagene dosed the first patient in a Phase 1 trial combining its antibody muzastotug with Incyte (NasdaqGS:INCY) asset INCA33890 for microsatellite stable color...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.